Example: Heart Attack

Clinical Trials on Parainfluenza Virus Type 3

Total 13 results

NCT01254175

Completed

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

Conditions: Parainfluenza Virus 3, Human
NCT00686075

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Conditions: Healthy
NCT04144348

Recruiting

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure

Conditions: Human Metapneumovirus and Human Parainfluenza Infection
NCT03462004

Active, not recruiting

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Conditions: Ebola Virus Disease
NCT02564575

Completed

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Conditions: Hemorrhagic Fever, Ebola
NCT00345670

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Conditions: Healthy
NCT00493285

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Conditions: Respiratory Viral Infections; Respiratory Syncytial Virus Infections; Parainfluenza Virus 3, Human
NCT00366782

Completed

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

Conditions: Paramyxoviridae Infections; Virus Diseases
NCT03392389

Completed

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Conditions: Human Metapneumovirus and Human Parainfluenza Infection
NCT00508651

Terminated

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Conditions: Healthy
NCT00308412

Completed

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

Conditions: Paramyxoviridae Infections; Virus Diseases
NCT01021397

Completed

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

Conditions: Paramyxoviridae Infections; Virus Diseases
NCT00111878

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Conditions: Respiratory Syncytial Virus Infections; Parainfluenza Infections